This program provides an efficient way to explore state-of-the-art AML and MDS treatment options and decision-making algorithms. In this session, you will learn about the role of allogeneic transplantation in patients with high-risk AML and MDS.
Daniel Weisdorf, M.D.
Professor of Medicine
Director, Adult Blood and Marrow Transplant Program
University of Minnesota
- Understand the role of risk stratification in treatment decision-making in high-risk AML and MDS
- Explain the rationale for HLA typing at diagnosis for patients with high-risk AML and MDS
- Compare the outcomes of matched related donor and matched unrelated donor transplants in patients with high-risk AML
- Describe influence of hematopoietic cell transplantation timing on outcomes in patients with MDS and high-risk AML
The goal of this activity is to provide physicians and other health care professionals with information that impacts the treatment algorithms for AML and MDS, such as the role of risk stratification, the outcomes of chemotherapy and transplantation and the state of current clinical trials.
This activity is intended for hematologists/oncologists, transplant physicians and other health care professionals.
If you have any questions regarding this program, call Renee Ryan at (800) 526-7809 ext. 8430, or e-mail firstname.lastname@example.org.